Table 1.
Clinical Characteristics of Participants
| Mepolizumab | Benralizumab | Prednisolone | P Value | |
|---|---|---|---|---|
| n | 6 | 6 | 6 | — |
| Age, yr* | 57 (53–64) | 68 (54–69) | 53 (46–67) | 0.5 |
| Females | 3 (50) | 2 (33) | 1 (17) | 0.8 |
| Ethnicity | ||||
| Caucasian | 6 (100) | 5 (83) | 6 (100) | 0.3 |
| African | — | 1 (17) | — | — |
| Sensitization to any respiratory allergens | 3 (50) | 4 (67) | 2 (33) | 0.5 |
| ICS BDP equivalent dose, mcg/d* | 2,000 (1,900–3,100) | 2,000 (1,750–2,000) | 2,000 (1,900–2,000) | 0.1 |
| No. OCS courses past 12 mo* | 8 (5–11) | 4 (3–6) | 3 (2–5) | 0.2 |
| FEV1% predicted* | 68 (37–78) | 71 (57–98) | 73 (57–87) | 0.4 |
| FVC % predicted* | 75 (69–89) | 87 (70–128) | 88 (73–96) | 0.4 |
| FEV1/FVC ratio* | 0.66 (0.41–0.84) | 0.71 (0.39–0.74) | 0.75 (0.57–0.81) | 0.4 |
| Blood eosinophil count, cells/μl† | 580 (1.3) | 724 (1.5) | 629 (1.6) | 0.5 |
| FeNO, ppb* | 41 (16–97) | 61 (33–130) | 50 (20–81) | 0.4 |
Definition of abbreviations: BDP = beclomethasone dipropionate; ICS = inhaled corticosteroids; OCS = oral corticosteroids; FeNO = fractional exhaled nitric oxide.
P values are for chi-test, Kruskall-Wallis test, or ANOVA. Results are expressed as number (percentage of the group) unless otherwise specified.
*
Median (interquartile range).
†
Geometric mean (geometric SD).